Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors DOI Open Access
Soňa Čierniková, Aneta Sevcikova,

Mária Novisedláková

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4271 - 4271

Published: Dec. 23, 2024

Immunotherapy with immune checkpoint inhibitors represents a revolutionary approach to the treatment of solid tumors, including malignant melanoma, lung cancer, and gastrointestinal malignancies. Anti-CTLA-4 anti-PD-1/PDL-1 therapies provide prolonged survival for cancer patients, but their efficacy safety are highly variable. This review focuses on crucial role gut microbiome in modulating toxicity blockade. Studies suggest that composition may influence response immunotherapy, specific bacterial strains able promote an anti-tumor response. On other hand, dysbiosis increase risk adverse effects, such as immune-mediated colitis. Interventions aimed at microbiome, use probiotics, prebiotics, fecal microbial transplantation, or dietary modifications, represent promising strategies reduce toxicity. The combination immunotherapy microbiome-based strategy opens up new possibilities personalized treatment. In addition, factors physical activity nutritional supplementation indirectly ecosystem consequently improve outcomes refractory leading enhanced patient responses survival.

Language: Английский

Therapeutic potential of microbiome modulation in reproductive cancers DOI
Mega O. Oyovwi, Benneth Ben‐Azu,

Kehinde Henrietta Babawale

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)

Published: April 6, 2025

Language: Английский

Citations

0
Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification DOI Creative Commons
Mingyao Huang,

Quansong Ji,

Huiyan Huang

et al.

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 1, 2025

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with limited treatment options at advanced stages. The gut microbiota, diverse community microorganisms residing in the gastrointestinal tract, plays pivotal role regulating immune responses through gut-liver axis. Emerging evidence underscores its impact on HCC progression and efficacy immunotherapy. This review explores intricate interactions between microbiota system HCC, focus key cells pathways involved tumor immunity. Additionally, it highlights strategies for modulating – such as fecal transplantation, dietary interventions, probiotics potential approaches to enhancing immunotherapy outcomes. A deeper understanding these mechanisms could pave way novel therapeutic aimed improving patient prognosis.

Language: Английский

Citations

0
Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors DOI Open Access
Soňa Čierniková, Aneta Sevcikova,

Mária Novisedláková

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4271 - 4271

Published: Dec. 23, 2024

Immunotherapy with immune checkpoint inhibitors represents a revolutionary approach to the treatment of solid tumors, including malignant melanoma, lung cancer, and gastrointestinal malignancies. Anti-CTLA-4 anti-PD-1/PDL-1 therapies provide prolonged survival for cancer patients, but their efficacy safety are highly variable. This review focuses on crucial role gut microbiome in modulating toxicity blockade. Studies suggest that composition may influence response immunotherapy, specific bacterial strains able promote an anti-tumor response. On other hand, dysbiosis increase risk adverse effects, such as immune-mediated colitis. Interventions aimed at microbiome, use probiotics, prebiotics, fecal microbial transplantation, or dietary modifications, represent promising strategies reduce toxicity. The combination immunotherapy microbiome-based strategy opens up new possibilities personalized treatment. In addition, factors physical activity nutritional supplementation indirectly ecosystem consequently improve outcomes refractory leading enhanced patient responses survival.

Language: Английский

Citations

1